Study Results

Savolitinib (ORPATHYS), 100 mg, film-coated tablets

Swiss marketing authorization number: 70151
Date of Swiss marketing authorization: 13.02.2026

Clinical trials

SAVANNAH (D5084C00007)
A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.

- EudraCT Nummer: 2018-003012-51
- ClinicalTrials.gov ID: https://www.clinicaltrials.gov/study/NCT03778229

Calquence, film-coated tablets, 100 mg

Swiss marketing authorization number: 68817
Date of Swiss marketing authorization: 07.10.2025

This medicinal product is subject to additional monitoring.

Indication extension:

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation (AMPLIFY)

- EudraCT Number: 2018-002443-28
- ClinicalTrials.gov ID: https://www.clinicaltrials.gov/study/NCT03836261

Calquence, film-coated tablets, 100 mg

Swiss marketing authorization number: 68817
Date of Swiss marketing authorization: 06.05.2025

This medicinal product is subject to additional monitoring.

Indication extension:

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma (ECHO)

- EudraCT Number: 2015-005220-26
- ClinicalTrials.gov ID: NCT02972840
- Study Details | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | ClinicalTrials.gov

Calquence, film-coated tablets, 100 mg

Swiss marketing authorization number: 68817
Date of Swiss marketing authorization: 07.03.2025

This medicinal product is subject to additional monitoring.

Indication extension:

An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma

- EudraCT Number 2014-002117-28
- ClinicalTrials.gov ID: NCT02213926
- Study Details | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | ClinicalTrials.gov

Wainzua (Eplontersen), 45 mg/0.8 ml, solution for injection in an autoinjector (injection) for subcutaneous use

Swissmedic Zulassungsnummer: 69332
Swissmedic Zulassungsdatum: 14.02.2025

Clinical trials

ION-682884-CS3
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

- EudraCT Nummer: 2019-001698-10
- Clinical Trials gov ID: NCT04136184
- ClinicalTrials.gov: https://www.clinicaltrials.gov/study/NCT04136184?cond=Polyneuropathy&term=eplontersen&rank=2

Capivasertib (Truqap), 160 mg and 200 mg, film-coated tablets

Swiss marketing authorization number: 69300
Date of Swiss marketing authorization: 19.03.2024

Clinical trials

CAPItello291 (D3615C00001)
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor

- EudraCT Nummer: 2019-003629-78
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04305496

Tremelimumab (Imjudo), Concentrate for solution for infusion, 20 mg/ml in single-dose vial for intravenous administration

Swiss marketing authorization number: 68706
Date of Swiss marketing authorization: 13.09.2023

Clinical trials

HIMALAYA
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

- EudraCT Nummer: 2016-005126-11
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT03298451

Anifrolumab (Saphnelo), 150 mg/ml in single-dose vial for intravenous administration, Concentrate for solution for infusion (sterile concentrate)

Swiss marketing authorization number: 68512
Date of Swiss marketing authorization: 31.08.2022

Clinical trials

D3461C00004
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

- EudraCT Nummer: 2014-004632-19
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02446899

D3461C00005
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

- EudraCT Nummer: 2014-004633-96
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02446912

CD-IA-MEDI-546-1013
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

- EudraCT Nummer: 2011-004296-36
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT01438489

Tezepelumab (Tezspire), 210 mg / 1.91 ml, Solution for injection in pre-filled syringe (injection) for subcutaneous use

Swiss marketing authorization number: 68454
Date of Swiss marketing authorization: 13.06.2022

Clinical trials

CD-RI-MEDI9929-1146
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma (PATHWAY)

- EudraCT Nummer: 2013-003269-33
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02054130

D5180C00007
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)

- EudraCT Nummer: 2017-003078-15
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT03347279

D5180C00009
Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SOURCE)

- EudraCT Nummer: 2017-003079-69
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT03406078

D5180C00018
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma (DESTINATION)

- EudraCT Nummer: 2018-002501-53
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT03706079

D5242C00001
Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT)

- EudraCT Nummer: 2020-003062-39
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04851964

D5180C00024
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SUNRISE)

- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05398263
- EudraCT Nummer: 2021-006691-17

D5180C00037
Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma (WAYFINDER)

- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05274815
- EudraCT Nummer: 2021-005457-85

Andexanet alfa (Ondexxya), 200 mg, Powder for solution for infusion

Swiss marketing authorization number: 67759
Date of Swiss marketing authorization: 02.12.2020

Clinical trials

14-503
A Phase 3 Randomized, Double-Blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Apixaban Anticoagulation With Intravenously Administered Andexanet Alfa

- ClinicalTrials.gov: https://www.clinicaltrials.gov/study/NCT02207725

14-504
A Phase 3 Randomized, Double-blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Rivaroxaban Anticoagulation With Intravenously Administered Andexanet Alpha

- ClinicalTrials.gov: https://www.clinicaltrials.gov/study/NCT02220725

14-505
Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)

- EudraCT Nummer: 2015-001785-26
- ClinicalTrials.gov: https://www.clinicaltrials.gov/study/NCT02329327

16-508
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects

- ClinicalTrials.gov: https://www.clinicaltrials.gov/study/NCT03310021

16-512
A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects

- ClinicalTrials.gov: https://www.clinicaltrials.gov/study/NCT03083704

18-513
A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor

- EudraCT Nummer: 2018-002620-17
- ClinicalTrials.gov: https://www.clinicaltrials.gov/study/NCT03661528